Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 10/20 | 0.62 |
| ▸ | RHEB | Q15382 | 3/20 | 0.37 |
| ▸ | PTGES | O14684 | 5/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966818 | 0.92 | S1PR2 (0.65) | S1PR2RHEB | |
| SCHEMBL23966815 | 0.90 | S1PR2 (0.63) | S1PR2RHEBCCNE2CCNE1CDK2 | |
| SCHEMBL23908839 | 0.90 | S1PR2 (0.75) | S1PR2RHEB | |
| SCHEMBL23908918 | 0.85 | S1PR2 (0.69) | S1PR2RHEBPTGES | |
| SCHEMBL23914694 | 0.84 | S1PR2 (0.76) | S1PR2 | |
| SCHEMBL23908779 | 0.84 | S1PR2 (0.65) | S1PR2RHEB | |
| SCHEMBL23915330 | 0.82 | S1PR2 (0.56) | S1PR2RHEB | |
| SCHEMBL23915328 | 0.82 | S1PR2 (0.68) | S1PR2 | |
| SCHEMBL23914851 | 0.80 | S1PR2 (0.49) | S1PR2 | |
| SCHEMBL23914693 | 0.78 | S1PR2 (0.82) | S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885RHEB 2911/4885PTGES 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.